Patent Application
20090209620
This invention was made in part with government support under Grant Nos. R01CA90327, R01CA101795, P50CA58204, P50CA093459 and PO1CA94237 awarded by the National Institutes of Health. The United States Government may have certain rights in the invention.
Naturally occurring CD4+ CD25+ regulatory T cells (Treg cells) and antigen-induced Treg cells induce self-tolerance by suppressing host immune responses, and thus play critical roles in the prevention of many autoimmune diseases. However, Treg cells can have detrimental effect on immunotherapy for cancer or other illnesses because they potently suppress immune responses elicited by vaccination or other systemic antigen stimulation. Increased proportions of CD4+ CD25+ Treg cells in total CD4+ T cell populations have been observed in patients with different types of cancers, including lung, breast and ovarian tumors. Antigen-specific CD4+ Treg cells from fresh tumor tissues from patients can be isolated and tumor infiltrating lymphocyte (TIL) lines established. These cells suppressed the proliferation of naive CD4+ T cells and inhibited interleukin (IL)-2 secretion by CD4+ effector cells through a cell-cell contact mechanism, and their suppressive function could not be reversed by a high concentration of IL-2. Thus, both naturally occurring CD4+ CD25+ and tumor-specific Treg cells present at tumor sites pose a major obstacle to successful immunotherapy for cancer and other diseases.
Toll-like receptors (TLRs) recognize a set of conserved molecular structures, so called pathogen associated molecular patterns (PAMPs), allowing them to sense and initiate innate and adaptive immune responses. Such responses are generally thought to be produced through the induction of a dendritic cell (DC) maturation program that enables DCs to activate naive T cells and to acquire the potential to control Treg cells. Stimulation of mouse DCs with TLR ligands such as lipopolysaccharide (LPS) and CpG DNA has been reported to induce DCs to secrete cytokines such as IL-6 and to render CD4+ effector cells refractory to Treg cell-mediated suppression.
The invention relates to a method for inhibiting the immunosuppressive capacity of CD4+ CD25+ Treg cells and antigen-induced Treg cells. The immunosuppressive activity of these cells is down regulated by short guanine containing oligonucleotides through the TLR8-IRKA4-MyD88 signal transduction pathway. The invention also discloses a method for identifying compounds which inhibit the immunosuppressive capacity of CD4+ CD25+ Treg cells and antigen-induced Treg cells. The method includes a comparison of cellular growth and/or division rates of parallel samples of näive CD4+ T cells. Näive CD4+ T cells exposed to uninhibited Treg cells are compared to control näive CD4+ T cells and näive CD4+ T cells exposed to Treg cells treated with a compound. The reversal of Treg suppression is measured by the relative growths of the variously treated näive CD4+ T cells. The invention also includes application of identified inhibitory compounds to decrease Treg cell mediated immunosuppression in the context of an organism suffering a disease such as an infection or cancer. The resultant increase in immune activity helps the organism's immune response to combat the disease state.
The foregoing has outlined rather broadly the features and technical advantages of the present invention in order that the detailed description of the invention that follows may be better understood. Additional features and advantages of the invention will be described hereinafter which form the subject of the claims of the invention. It should be appreciated by those skilled in the art that the conception and specific embodiment disclosed may be readily utilized as a basis for modifying or designing other structures for carrying out the same purposes of the present invention. It should also be realized by those skilled in the art that such equivalent constructions do not depart from the spirit and scope of the invention as set forth in the appended claims. The novel features which are believed to be characteristic of the invention, both as to its organization and method of operation, together with further objects and advantages will be better understood from the following description when considered in connection with the accompanying figures. It is to be expressly understood, however, that each of the figures is provided for the purpose of illustration and description only and is not intended as a definition of the limits of the present invention. All articles, papers and other references cited herein are incorporated by reference. This incorporation by reference includes the articles, papers and other references listed within or otherwise cited by these incorporated articles, papers and other references.
For a more complete understanding of the present invention, reference is now made to the following descriptions taken in conjunction with the accompanying drawing, in which:
Definitions
As used herein, the use of the word “a” or “an” when used in conjunction with the term “comprising” in the claims and/or the specification may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.” Still further, the terms “having,” “including,” “containing” and “comprising” are interchangeable and one of skill in the art is cognizant that these terms are open ended terms. Some embodiments of the invention may consist of or consist essentially of one or more elements, method steps, and/or methods of the invention. It is contemplated that any method or composition described herein can be implemented with respect to any other method or composition described herein.
Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. For purposes of the present invention, the following terms are defined below.
“An effective amount” is a concentration of oligonucleotide in a Treg cell's environment capable of inhibiting the Treg cell's immunosuppressive activity. The term “therapeutically effective amount” as used herein refers to an amount that results in an improvement or remediation of the symptoms of the disease or condition.
The term “nucleic acid” is well known in the art. A “nucleic acid” as used herein will generally refer to a molecule (i.e., a strand) of DNA, RNA or a derivative or analog thereof, comprising a nucleobase. A nucleobase includes, for example, a naturally occurring purine or pyrimidine base found in DNA (e.g., an adenine “A,” a guanine “G,” a thymine “T” or a cytosine “C”) or RNA (e.g., an A, a G, an uracil “U” or a C). The term “nucleic acid” encompass the terms “oligonucleotide” and “polynucleotide,” each as a subgenus of the term “nucleic acid.” The term “oligonucleotide” refers to a molecule of between about 3 and about 100 nucleobases in length. The term “polynucleotide” refers to at least one molecule of greater than about 100 nucleobases in length. These definitions generally refer to a single-stranded molecule, but in specific embodiments will also encompass an additional strand that is partially, substantially or fully complementary to the single-stranded molecule. Thus, a nucleic acid may encompass a double-stranded molecule or a triple-stranded molecule that comprises one or more complementary strand(s) or “complement(s)” of a particular sequence comprising a molecule. As used herein, a single stranded nucleic acid may be denoted by the prefix “ss,” a double stranded nucleic acid by the prefix “ds,” and a triple stranded nucleic acid by the prefix “ts.” Preferably, in nucleic acids comprising natural organic bases, the bases are unmethylated. Nucleic acid molecules can be obtained from existing nucleic acid sources but are preferably synthetic.
The term “library” includes searchable populations of small molecules or mixtures of molecules. In one embodiment, the library is comprised of samples or test fractions (either mixtures of small molecules or isolated small molecules) which are capable of being screened for activity. For example, the samples could be added to wells in a manner suitable for high throughput screening assays. In a further embodiment, the library could be screened for binding compounds by contacting the library with a target of interest, e.g., a live cell, a protein or a nucleic acid.
“Type D CpG oligonucleotides” are well known in the art as disclosed by U.S. Pat. No. 6,977,245 which is incorporated by reference. Type D CpG oligonucleotides generally contain a CpG dinucleotide sequence and a stretch of 4 or more contiguous guanine residues. Type D CpG oligonucleotides are generally between 18 and 30 nucleotides in length, and may contain one or more of the following sequence content:
where X may be any nucleobase or none.
A “non CpG containing recombinant DNA” is a recombinant DNA that is does not contain a CpG dinucleotide sequence.
A “nuclease resistant inter-residue backbone linkage” is a chemical linkage between organic bases in a nucleic acid that is more resistant to in vivo nuclease degradation as compared to naturally occurring phosphodiester linkages. The preferred chemical linkage is a phosphorothioate (i.e., at least one of the phosphate oxygens of the nucleic acid molecule is replaced by sulfur) or phosphorodithioate modified nucleic acid molecules. Other stabilized nucleic acid molecules include: nonionic DNA analogs, such as alkyl- and aryl-phosphonates, phosphodiester and alkylphosphotriesters, in which the charged oxygen moiety is alkylated. Nucleic acid molecules which contain a diol, such as tetraethyleneglycol or hexaethyleneglycol, at either or both termini have also been shown to be substantially resistant to nuclease degradation.
A “nuclease sensitive inter-residue backbone linkage” is a phosphodiester linkage between organic bases in a nucleic acid or alternative known in the art which degrades in vivo from nuclease activity at least at the same rate as a phosphodiester linkage.
An “immunogenic composition” is any composition capable of eliciting an immune response in a subject upon administration. The term “vaccine” as used herein is defined as material used to provoke an immune response (e.g., the production of antibodies) on administration of the materials and thus conferring immunity. Thus, a vaccine is an antigenic and/or immunogenic composition.
“Regulatory T cells” (Treg cells) are a functionally defined subset of CD4+ T lymphocytes. Treg cells function in vivo to control immunological reactivity to self antigens. This function is manifested by Treg cells' ability to suppress the activation of näive immune effector cells (CD4+ and CD8+ ) such as CD4+ CD25− T cells. Two major classes of Treg cells are the thymically derived natural Treg cells and antigen induced Treg cells. Naturally occurring Treg cells mediate immunotolerance of self-antigens and their dysregulation may play a role in autoimmune diseases. Antigen induced Treg cells are induced by peripheral antigen stimulation. This subcategory of Treg cells is found among tumor infiltrating lymphocytes and mediates tolerance of tumor antigens. While Treg cell activation can be antigen specific, Treg immunosuppression is not. Thus, Treg activity creates a globally suppressive immunological state. Treg cells have been characterized as a subpopulation of CD4+ T-cells expressing the IL-2 receptor CD25. However, some experiments demonstrate that CD25 may not be expressed by Treg cells under some conditions. Other molecular markers strongly associated with Treg cells are the transcription factor, FOXP3, and glucocorticoid-induced tumor necrosis factor receptor family-related gene (GITR, also known as TNFRSF18). However, none of these molecular markers are determinate of Treg identity or completely correlate with Treg immunosuppression activity.
“Cytokines” are small secreted proteins which mediate and regulate immunity, inflammation, and hematopoiesis. They must be produced de novo in response to an immune stimulus. They generally (although not always) act over short distances and short time spans and at very low concentration. They act by binding to specific membrane receptors, which then signal the cell via second messengers, often tyrosine kinases, to alter its behavior. Responses to cytokines include increasing or decreasing expression of membrane proteins (including cytokine receptors), proliferation, and secretion of effector molecules. Cytokine is a general name; other names include lymphokine (cytokines made by lymphocytes), monokine (cytokines made by monocytes), chemokine (cytokines with chemotactic activities), and interleukin (cytokines made by one leukocyte and acting on other leukocytes). Cytokines may act on the cells that secrete them (autocrine action), on nearby cells (paracrine action), or in some instances on distant cells (endocrine action). Cytokines are made by many cell populations, but the predominant producers are helper T cells (Th) and macrophages. The largest group of cytokines stimulates immune cell proliferation and differentiation. This group includes Interleukin 1 (IL-1), which activates T cells; IL-2, which stimulates proliferation of antigen-activated T and B cells; IL-4, IL-5, and IL-6, which stimulate proliferation and differentiation of B cells; Interferon gamma (IFNg), which activates macrophages; and IL-3, IL-7 and Granulocyte Monocyte Colony-Stimulating Factor (GM-CSF), which stimulate hematopoiesis.
“Subject” is an organism being given a nucleic acid according to the methods disclosed by the Specification. Preferably a subject expresses a functional TLR8 on the subject's Treg cells. Preferably, a subject is a mammal other than mice (which do not express a functional TLR8), more preferably human.
The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, recombinant DNA, and so forth which are within the skill of the art. Such techniques are explained fully in the literature. See e.g., Sambrook, Fritsch, and Maniatis, MOLECULAR CLONING: A LABORATORY MANUAL, Second Edition (1989), OLIGONUCLEOTIDE SYNTHESIS (M. J. Gait Ed., 1984), ANIMAL CELL CULTURE (R. I. Freshney, Ed., 1987), the series METHODS IN ENZYMOLOGY (Academic Press, Inc.); GENE TRANSFER VECTORS FOR MAMMALIAN CELLS (J. M. Miller and M. P. Calos eds. 1987), HANDBOOK OF EXPERIMENTAL IMMUNOLOGY, (D. M. Weir and C. C. Blackwell, Eds.), CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (F. M. Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J. G. Siedman, J. A. Smith, and K. Struhl, eds., 1987), CURRENT PROTOCOLS IN IMMUNOLOGY (J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach and W. Strober, eds., 1991); ANNUAL REVIEW OF IMMUNOLOGY; as well as monographs in journals such as ADVANCES IN IMMUNOLOGY.
Description
A new class of immunologically active oligonucleotides are disclosed. These immunologically active oligonucleotides act through Toll-Like Receptor 8 (TLR8) to activate the TLR8-IRKA4-MyD88 signal transduction pathway in regulatory T cells (Treg cells). This signaling down regulates Treg cell activity leading to a derepression of immunological activity. In one embodiment, this new class of immunologically active oligonucleotides includes oligonucleotides with a guanosine and a partially stabilized or nuclease resistant inter-residue backbone. A representative group of oligonucleotides is shown in
Another embodiment of the invention shown in relates to methods for inhibiting the immunosuppressive capacity of Treg cells utilizing this new class of immunologically active oligonucleotides. As shown in
Another embodiment of the invention relates to a new method for identifying compounds which inhibit the immunosuppressive capacity of CD4+ CD25+ Treg cells and antigen-induced Treg cells. In a preferred embodiment, demonstrated in
Establishing Treg cell lines and purifying natural CD4+ CD25+ Treg cells CD4+ Treg clones were established from CD4+ tumor-infiltrating lymphocytes (TIL102 and TIL164) and maintained in RPMI 1640 medium containing 10% human AB serum and recombinant IL-2 (300 IU/ml) using methods well known in the art (See, e.g., H. Y. Wang et al., Immunity 20, 107-118 (2004)). Treg clones derived from TIL102 or TIL164 cells were pooled and designated Treg102 or Treg164. Naturally occurring CD4+ CD25+ Treg cells were obtained by sorting CD4+ T cell populations from fresh PBMCs after staining with anti-CD4 and anti-CD25 antibodies. To obtain optimal expansion, the OKT3 expansion method was performed using methods well known in the art (See, e.g., H. Y. Wang et al., Immunity 20, 107-118 (2004)). T cell clones were maintained at a low IL-2 concentration (300 IU/ml). Melanoma cell lines and EBV-transformed B-cell lines used in this study were cultured in RPMI 1640 medium containing 10% FCS. Human embryonic kidney (HEK) 293 and Epstein-Barr virus (EBV)-transformed B cell lines were maintained in RPMI 1640 with 10% fetal calf serum (FCS).
Assays for Treg Suppression of Näive T Cell Proliferation
A. Proliferation assay with Dendritic Cells (DCs): Näive CD4+ T cells were purified from PBMCs using microbeads (Miltenvi Biotec). DCs were generated from PBMC-derived monocytes in the presence of IL-4 (500 ng/ml) and GM-CSF (800 ng/ml) for 7 days. 1×105 näive CD4+ T cells were cultured with regulatory T cells at different ratios (1: 0.2, 1:0.1 and 1:0.05) in 200 ul of medium containing 2×104 of DCs and anti-CD3 antibody (100 ng/ml) plus one of the following TLR ligands or cytokines: CpG-A (3 ug/ml), CpG-B (3 ug/ml), LPS (100 ng/ml), TNF.-α (20 ng/ml), IFN-α (100 ng/ml), or IL-6 (100 ng/ml). After 56 h of culture, [3H]thymidine was added at a final concentration of 1 uCi/well, followed by an additional 16 h. of culture. The incorporation of [3H]thymidine was measured with a liquid scintillation counter, using methods well known in the art (See, e.g., M. K. Levings et al., J. Exp. Med. 196, 1335-46 (2002)). All experiments were performed in triplicate.
B. Proliferation assay without DCs: 1×105 näive CD4 T cells were cultured with regulatory T cells at different ratios (1: 0.2, 1:0.1 and 1:0.05) in anti-CD3 mAb-coated (2 ug/ml) 96-well plates in the presence or absence of the following TLR ligands or cytokines: CpG-A (3 ug/ml), CpG-B (3 ug/ml), LPS (100 ng/ml), TNF.-α (20 ng/ml), IFN-α (100 ng/ml), or IL-6 (100 ng/ml). After 56 h of culture, [3H]thymidine was added at a final concentration of 1 uCi/well, followed by an additional 16 h of culture. The incorporation of [3H]thymidine was measured with a liquid scintillation counter.
C. Pretreatment of Treg cells: 1×106 Treg cells were cultured in medium containing CpG-A (3 ug/ml), CpG-B (3 ug/ml), LPS (100 ng/ml), TNF.-α (20 ng/ml), IFN-α (100 ng/ml) or IL-6 (100 ng/ml) for 3 days. After three washes, the pretreated Treg cells were cultured with näive CD4+ T cells in anti-CD3 mAb-coated plates (without DCs) to determine their suppressive function. After 56 h of culture, [3H]thymidine was added at a final concentration of 1 uCi/well, and cultured for an additional 16 h. The incorporation of [3H]thymidine was measured with a liquid scintillation counter.
FACS Analysis
The expression of CD4, CD25 and GITR on Treg cells was determined by FACS analysis after staining with specific antibodies (purchased from R&D Systems and BD Biosciences). To isolate naturally occurring CD4+ CD25+ Treg cells, CD4+ T cells were stained with anti-CD4 and anti-CD25 antibodies conjugated to either PE or FITC. After washing, the cells were sorted by FACSARIA into CD4+ CD25+ and CD4+ CD25− T cell populations. For experiments with carboxyfluorescein diacetate succinimidyl ester (CFSE)-labeled cells, näive CD4+ T cells or Treg cells (1×107) were stained with CFSE (4.5 uM) from Molecular Probes at 37° C. for 15 min. After several washes, the labeled cells were cultured in RPMI 1640 containing 10% human AB serum and IL-2 (300 IU/ml). To determine suppression of cell division by Treg cells, unlabeled Treg cells were added to CFSE-labeled näive T cells at an 1:1 ratio in 24-well plates precoated with OKT3 (2 ug/ml) in the presence or absence of CpG-A or Poly-G2 (3 ug/ml). After 3 days in culture, the cells were analyzed by FACS gating on the CFSE-labeled cells.
rtPCR and Quantitative PCR
Total RNA was extracted from T cells with Trizol reagent (Invitrogen, Inc. San Diego, Calif.) and SuperScript II RT kit, reverse transcription (Invitrogen, Inc. San Diego, Calif.). A 20-μl reverse transcription mixture containing 2 μg of total RNA was incubated at 42° C. for 1 h. TLR7, 8 and 9 mRNA levels were quantified by real-time PCR with ABI/PRISM7000 sequence detection system (PE Applied Biosystems, Inc. Foster City, Calif.). PCR reactions were performed with primers, an internal fluorescent TaqMan probe specific to TLR7, 8, 9, MyD88, IRAK4 or HPRT (purchased from PE Applied Biosystems Inc., Foster City, Calif.). TLR7, 8 and 9, MyD88 and IRAK4 mRNA levels in each sample were normalized to the relative quantity of HPRT. All samples were run in triplicate. For specific knockdown of TLR8, MyD88 and IRAK4 in Treg cells, Treg cells were infected with the corresponding siRNA for each gene and sorted them into transduced (GFP+) and untransduced (GFP−) cell populations. Total RNA was extracted from both transduced (GFP+) and untransduced (GFP−) cell populations to determine the expression level of a relevant gene by real-time PCR. The expression level of an irrelevant gene served as a control. For conventional reverse-transcription PCR, gene-specific primers were used and the reactions run for 28 cycles of 94° 2 min for initial denature, 28 cycles of 94° for 30 s, 56° for 30 s and 72° for 45 s, followed by extension at 72° for 10 min. PCR products were separated on 1% agarose gel.
The following primers were used for TLR7
for TLR8
and for TLR9
Lentivirus-Based siRNAs
Several siRNA sequences (19 nucleotides) for each gene were selected with use of computer-assisted programs. Oligonucleotides containing a siRNA sequence, 8 nucleotide spacers, and a polyT terminator sequence were annealed and then cloned into the HapI and XhoI sites of GFP-expressing pLentilox3.7 vector using methods well known in the art (See, e.g., D. A. Rubinson et al., Nat. Genet. 33, 401-6 (2003)). siRNA was under the control of a U6 promoter. The following DNA sequences used to construct siRNAs for IRAK4, MyD88, and TLR7, 8 and 9, were effective in silencing their corresponding genes:
Western Blotting and RNA Interference
To evaluate the expression levels of each gene, IRAK4 and MyD88 were cloned into FLAG-tagged pcDNA3 expression vector, and inserted TLR7, 8, 9 into an HA-tagged pcDNA3 expression vector. 293 T cells (1.2×106/well) were seeded on 6-well plates for 4 h, and then transfected with 2 μg of plasmid encoding a target gene plus/minus the corresponding or control siRNA plasmid DNAs (2 μg) using Lipofectamine 2000. 48 h later, the transfected cells were lysed and the samples were separated by SDS-PAGE. After the transfer of protein to a PVDF membrane, the expression of a target protein was probed with either an anti-FLAG antibody (M2) for MyD88 and IRAK4 or an anti-HA antibody for TLR7, 8, or 9, followed by a second horseradish peroxidase-conjugated antibody. Beta-actin served as a control for sample loading and was detected with an anti-actin antibody. Western blots were developed with Chemiluminescent Substrate (KPL, Maryland) and visualized on a Kodak Image Station (Eastman Kodak Co.).
Preparation of Lentiviral Supernatants and Transduction of T Cells
5×106 293T cells were pre-seeded onto 100-mm dishes and transfected with 12 μg siRNA lentiviral DNA, 12 μg VSV-G plasmid DNA and 12 μg packaging viral CMV delta 8.9 plasmid, using Lipofectamine 2000. After the addition of fresh culture medium 8 h later, the cells were cultured for an additional 2-3 days. Viral supernatants were harvested, passed through a 0.45 μM filter and concentrated by ultracentrifugation at 20,000 rpm for 2 h. Virus pellets were resuspended in a small volume of medium, and viral titers were determined by infecting 293T cells with serially diluted doses of virus. For transduction of T cells, T cells (2×106 ) were first activated by OKT3 (2 ug/ml)-coated plates and then were mixed with the concentrated lentiviral supernatant with a multiplicity of infection (MOI) of 10-15 in a total volume of 0.5 ml T cell medium containing 8 ug/ml polybrene (Sigma), and then span at 1000×g for 1 h at room temperature. After 16 h of incubation, 0.5 ml of T cell medium was added to each well. Forty-eight hours later, the T cells were transduced again with the same concentrated viral supernatants. Transduction efficiency was analyzed at 3 or 4 days post-transduction, and the cells were sorted into GFP+and GFP−cells with a FACS ARIA sorter. The sorted cells (GFP+and GFP−) and untransduced Treg cells were then used to determine their reversibility by Poly-G10 in functional proliferation assays.
TLR Ligand Assays
Näive CD4 T+cells were purified from PBMCs by using microbeads (Miltenvi Biotec). Näive CD4+ T cells (105/well) were cultured with regulatory T cells at a ratio of 10:1 in OKT3 (2 ug/ml)-coated, U bottomed 96-well plates containing the following ligands: LPS (100 ng/ml), imiquimod (10 μg/ml), loxoribine (500 μM), poly(I:C) (25 μg/ml), ssRNA40/LyoVec (3 μg/ml), ssRNA33/LyoVec (3 μg/ml), pam3CSK4 (200 ng/ml) and flagellin (10 μg/ml) were purchased from Invivogene (San Diego, Calif.), while CpG-A (3 μg/ml), CpG-B (3 μg/ml) and Poly-G oligonucleotides (3 μg/ml) were synthesized in Integrated DNA Technologies, Inc (Coralville, Iowa). Functional assays were identical to those described above.
Rag 1 −/− and Rag 2 −/− γC −/− mouse experiments
Human 586mel tumor cells (5×106) in 100 μl of buffered saline were subcutaneously injected into Rag1−/− mice (lacking T and B cells) or Rag 2 −/− γC −/− mice (lacking T, B and NK cells) on day 0. Tumor-specific CD8+ TIL586 cells (2.5×107), which recognize and kill 586mel cells, were injected intravenously on day 3 with or without Treg102 cells (3×106) pretreated with Poly-G10 or Poly-T10. Tumor size was measured with calipers every 2-3 days. Tumor volume was calculated on the basis of two-dimensioned measurements. Tumor growth curves were compared with the Wilcoxon rank-sum test.
Reversal of the suppressive function of CD4+ Treg cells by CpG-A.
Two CD4+ Treg cell lines, designated Treg102 and Treg164, were generated with a panel of Treg cell clones derived from TIL102 and TIL164 cells. As expected, both lines effectively suppressed CD4+ CD25− naive T cell proliferation in medium containing soluble anti-CD3 antibody (100 ng/ml) and human DCs, which were generated from peripheral blood mononuclear cell (PBMC)-derived monocytes in medium containing GM-CSF (800 ng/ml) and IL-4 (500 ng/ml) after 7 days of culture (
Näive CD4+ T cell proliferation experiments were performed similar to those in
To exclude the possibility that the purified naive CD4+ T cells might have been contaminated with a small number of monocytes or DCs, cultured CD4+ Treg cells (100% purity) were pretreated with CpG-A (SEQ ID NO: 1) for 3 days. After three washes, the pretreated CD4+ Treg cells were mixed with naive CD4+ T cells in anti-CD3 antibody-coated plates to evaluate their ability to suppress the proliferation of naive CD4+ T cells. As shown in
To determine whether the CpG motif in CpG A confers the ability to reverse the suppressive function of CD4+ Treg cells, CD4+ Treg cell lines were pretreated for 3 days with CpG-A (SEQ ID NO: 1), non-CpG-A (CG changed to GC in CpG-A; SEQ ID NO: 3), CpG B (SEQ ID NO: 2) or non-CpG-B (CG changed to GC in CpG-B; SEQ ID NO: 4), and used them in proliferation assays following extensive washes. Pretreatment with either CpG-A (SEQ ID NO: 1) or non-CpG-A (SEQ ID NO: 3) reversed the suppressive activities of CD4+ Treg cells equally well. In contrast, CpG-B (SEQ ID NO: 2) and non-CpG-B (SEQ ID NO: 4) lacked any discernible effect (
Identification of sequence elements in CpG-A responsible for the direct reversal of the suppressive function of CD4+ Treg cells.
To further define the CpG-A (SEQ ID NO: 1) sequences responsible for the observed reversal effect, CpG-NG (SEQ ID NO: 5) and Poly-G10 (SEQ ID NO: 6), were tested for their ability to reverse the suppressive function of Treg cells. Naive CD4+ T cells were mixed with CD4+ Treg cells in anti-CD3 antibody-coated 96-wells with 200 μl of medium containing CpG-NG (SEQ ID NO: 5), CpG-A (SEQ ID NO: 1) or Poly-G10 (SEQ ID NO: 6). The proliferation assay was conducted as described in
A series of oligonucleotides with decreasing numbers of guanosine nucleosides was constructed to determine the minimal number required for the reversal effect. For the experiments in
MyD88-IRAK4 pathway is required for reversing the suppressive function of Treg cells.
The current model of TLR signaling pathways predicts that TLR1, 2, 5, 6, 7, 8, and 9 use MyD88 as their sole receptor-proximal adaptor to transduce signals, TLR3 uses interferon-regulated factor 3 (IRF3) for the production of IFN-α in response to pathogen recognition, while TLR4 is linked to both MyD88-dependent and MyD88 independent pathways. Since MyD88 is important for the signaling activities of most TLRs, it stood to reason that its dependent pathway, in which IRKA4 transduces signals from MyD88 to TRAF6 and other downstream molecules, would likely be involved in TLR signaling initiated by guanosine-containing oligonucleotides. Four or five eGFP-expressing lentiviral constructs containing U6-driven siRNAs were made for each gene and were tested their abilities to specifically knock down their respective target proteins. Representative data for functional IRAK4 and MyD88 siRNA constructs are shown in
This data demonstrates that direct reversal of the suppressive activity of Treg cells by guanosine containing oligonucleotides relies on TLR signal transduction through the MyD88-IRAK4 pathway. Hence, the receptors for such ligands must be limited to those using MyD88-IRAK4 as their sole or primary signaling pathway. A review of the properties of all known TLR ligands indicated that TLR3, 7, 8 and 9 would be the most likely candidates for binding nucleotide-related ligands. Although TLR3 recognizes double-stranded RNA, it relies on a MyD88-IRAK4-independent signaling pathway. TLR7, 8 and 9, which form an evolutionary cluster, are thought to reside in endosomes and to initiate signaling through the MyD88-IRAK4 pathway. TLR9 has been identified as a receptor for CpG oligonucleotides, while TLR7 and 8 function as receptors for synthetic guanosine analogs (loxoribine and imidazoquinoline) and single-stranded RNA. Although some TLRs have been reported to be expressed by mouse CD4+ CD25+ Treg cells, their expression by human CD4+ Treg cells are first demonstrated by the data herein.
TLR8 is the receptor responsible for guanosine oligonucleotide-induced reversal of the suppressive function of Treg cells.
Reverse-transcription PCR revealed that neither TLR7 nor TLR9 was expressed in antigen specific Treg cell lines, CD4+ CD25+ Treg cells or CD4+ CD25− T cells, although TLR7 was highly expressed in DC, and EBV-transformed B cells (
On the basis of the expression pattern of TLR7, 8 and 9 in Treg cells, TLR8 was the likely receptor for guanosine containing oligonucleotides. Several lentiviral siRNA constructs were screened against TLR7, 8 and 9. Representative data for functional knock down of TLR7, 8 and 9 by the corresponding siRNAs are shown in
If the TLR8-MyD88-IRAK4 signaling pathway is necessary and sufficient for direct reversal of the suppressive function of Treg cells, it should be possible to produce that effect with natural ligands for human TLR8. For
The data in
Treg cells were pretreated with Poly-G2 (SEQ ID NO: 15) in different concentrations of chloroquine to examine whether acidification is required for the function of guanosine containing oligonucleotides. After extensive washes, the pretreated Treg cells were used for functional assays. The reversal effect of Poly-G2 (SEQ ID NO: 15) oligonucleotides decreased with increasing concentrations of chloroquine, suggesting that binding and activation of TLR8 in endosomes by either guanosine containing DNA or RNA oligonucleotides is the key step in reversal of Treg suppressive function.
Proliferation and Cytotoxicity of Treg Cells
Identification and titration of sequence elements in CpG-A responsible for the direct reversal of Treg cell suppressive function.
B. Dose response relationships for the reversibility of Treg cells by A4G1, C4G1 and T4G1 oligonucleotides. Experiments were performed as in panel A.
Purification and suppressive function of CD4+ CD25+ Treg cells and their functional reversal by Poly-G5.
Knockdown of IRAK4. MyD88, TLR7, TLR8 and TLR9 by RNA interference.
The MyD88-IRAK4 pathway is required to reverse the suppressive function of Treg164 cells.
Expression level of TLR7 and 8 in Treg cells determined by real-time PCR analysis in different cell lines with gene-specific primers.
Although the present invention and its advantages have been described in detail, it should be understood that various changes, substitutions and alterations can be made herein without departing from the spirit and scope of the invention as defined by the appended claims. Moreover, the scope of the present application is not intended to be limited to the particular embodiments of the process, machine, manufacture, composition of matter, means, methods and steps described in the specification. As one of ordinary skill in the art will readily appreciate from the disclosure of the present invention, processes, machines, manufacture, compositions of matter, means, methods, or steps, presently existing or later to be developed that perform substantially the same function or achieve substantially the same result as the corresponding embodiments described herein may be utilized according to the present invention. Accordingly, the appended claims are intended to include within their scope such processes, machines, manufacture, compositions of matter, means, methods, or steps.
This application claims the benefit of Provisional U.S. application 60/660,028, the contents of which are incorporated by reference into this application.
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/US2006/008379 | 3/9/2006 | WO | 00 | 9/24/2008 |
| Number | Date | Country | |
|---|---|---|---|
| 60660028 | Mar 2005 | US |
